Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $40.80 | Total: $204.00 |
| 1 | 10 | $34.56 | Total: $345.60 |
| 1 | 25 | $29.28 | Total: $732.00 |
| 1 | 50 | $24.96 | Total: $1,248.00 |
| 1 | 100 | $21.60 | Total: $2,160.00 |
Overview
ERK-IN-3 (ASN007 free base) is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.
Chemical Properties
| Molecular Formula | C22H25ClFN7O2 |
| Molecular Weight | 473.93 |
| CAS Numbers | 2055597-12-9 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | Cc1cnc(NC2CCOCC2)nc1-n1cnc(c1)C(=O)N[C@H](CN)c1cc(F)cc(Cl)c1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Sanjeeva PR, et, al. Abstract B150 ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models. Molecular Cancer Therapeutics. 2018 Jan; 17[1].